Evidence map›Paper›PMID 35122388›Full record

ArticleMolecular oncology2022

A new function for the serine protease HtrA2 in controlling radiation-induced senescence in cancer cells.

Liat Hammer, Vered Levin-Salomon, Naama Yaeli-Slonim, Moria Weiss, Naama P Dekel-Bird, Tsviya Olender, Ziv Porat, Sabina Winograd-Katz, Alon Savidor, Yishai Levin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Liat HammerDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-4309-5495
Vered Levin-SalomonDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Naama Yaeli-SlonimDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Moria WeissDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Naama P Dekel-BirdDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Tsviya OlenderDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Ziv PoratDepartment of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Sabina Winograd-KatzDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Alon SavidorThe Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), Weizmann Institute of Science, Rehovot, Israel.
Yishai LevinThe Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), Weizmann Institute of Science, Rehovot, Israel.
Shani BialikDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Benjamin GeigerDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Adi KimchiDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-8236-8989
Weizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy can induce cellular senescence in cancer cells, leading to short-term tumor growth arrest but increased long-term recurrence. To better understand the molecular mechanisms involved, we developed a model of radiation-induced senescence in cultured cancer cells. The irradiated cells exhibited a typical senescent phenotype, including upregulation of p53 and its main target, p21, followed by a sustained reduction in cellular proliferation, changes in cell size and cytoskeleton organization, and senescence-associated beta-galactosidase activity. Mass spectrometry-based proteomic profiling of the senescent cells indicated downregulation of proteins involved in cell cycle progression and DNA repair, and upregulation of proteins associated with malignancy. A functional siRNA screen using a cell death-related library identified mitochondrial serine protease HtrA2 as being necessary for sustained growth arrest of the senescent cells. In search of direct HtrA2 substrates following radiation, we determined that HtrA2 cleaves the intermediate filament protein vimentin, affecting its cytoplasmic organization. Ectopic expression of active cytosolic HtrA2 resulted in similar changes to vimentin filament assembly. Thus, HtrA2 is involved in the cytoskeletal reorganization that accompanies radiation-induced senescence and the continuous maintenance of proliferation arrest.

Indexed as

Cellular SenescenceHigh-Temperature Requirement A Serine Peptidase 2NeoplasmsProteomicsApoptosisHumansMitochondrial ProteinsTumor Cells, CulturedVimentinHigh-Temperature Requirement A Serine Peptidase 2Mitochondrial ProteinsVimentincellular senescenceHtrA2/Omiradiation therapysiRNA functional screenvimentin

Identifiers

PMID35122388
PMCPMC8936513
OpenAlexW4210245242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.